Restoration of erythropoiesis by rituximab in an adult patient with primary acquired pure red cell aplasia refractory to conventional treatment

被引：33

作者：

Auner, HW ^{[1
]}

Wölfler, A

Beham-Schmid, C

Strunk, D

Linkesch, W

Sill, H

机构：

[1] Karl Franzens Univ Graz, Dept Med, Div Haematol, Graz, Austria

[2] Karl Franzens Univ Graz, Inst Pathol, Graz, Austria

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2002年 / 116卷 / 03期

关键词：

pure red cell aplasia; rituximab; CD20;

D O I：

10.1046/j.1365-2141.2002.3317_3.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：727 / 728

页数：2

共 4 条

[1] The pathophysiology of pure red cell aplasia: Implications for therapy [J].

Charles, RJ ;

Sabo, KM ;

Kidd, PG ;

Abkowitz, JL .

BLOOD, 1996, 87 (11) :4831-4838

[2]

DESSYPRIS EN, 2000, HEMATOLOGY BASIC PRI, P342

[3] Rituximab chimeric Anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma:: Half of patients respond to a four-dose treatment program [J].

McLaughlin, P ;

Grillo-López, AJ ;

Link, BK ;

Levy, R ;

Czuczman, MS ;

Williams, ME ;

Heyman, MR ;

Bence-Bruckler, I ;

White, CA ;

Cabanillas, F ;

Jain, V ;

Ho, AD ;

Lister, J ;

Wey, K ;

Shen, D ;

Dallaire, BK .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2825-2833

[4] Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia [J].

Zecca, M ;

De Stefano, P ;

Nobili, B ;

Locatelli, F .

BLOOD, 2001, 97 (12) :3995-3997

← 1 →